Skip to main content
Clinical Trials/NL-OMON28418
NL-OMON28418
Recruiting
Not Applicable

Advanced neuroimaging, biomarkers, clinical and cognitive functioning in early MS

Bristol Myers Squibb0 sites180 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Bristol Myers Squibb
Enrollment
180
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations;
  • 2\. All participants should be 18\-65 years of age;
  • 3\. Sufficient Dutch proficiency to be able to comprehend and to perform the neuropsychological examination;
  • 4\. All participants need to meet the safety criteria to undergo an MRI examination;
  • For the patients specifically:
  • 5\. Only patients that are recently (up to 12 months) diagnosed with clinically definite MS according to the 2017 revision of the McDonald MS criteria will be included;
  • 6\. Only patients with (active) relapsing\-remitting disease course will be included;
  • 7\. All types of disease modifying treatment for MS are allowed.

Exclusion Criteria

  • 1\. Unable or unwilling to provide informed consent;
  • 2\. Presence or history of alcohol or drug abuse;
  • 3\. Presence or history of psychiatric or neurological disease of the CNS (for patients: neurological disease other than MS) that is expected to affect any of the outcome measures (will be discussed with the principal investigator and neurologist);
  • 4\. Presence of contra\-indications for MRI;
  • 5\. Participation in other (scientific) studies using cognitive or physical training programs (interventions other than standard care) at baseline to avoid noise.
  • For the patient groups specifically:
  • 6\. Patients with disease categorized as clinically isolated syndrome, primary progressive, secondary progressive or progressive relapsing;
  • 7\. Relapses or steroid treatment less than four weeks prior to the visits. Visits of included patients experiencing a relapse will be postponed if possible;
  • 8\. Patients undergoing a cognitive relapse. Visits of included patients experiencing a cognitive relapse will be postponed if possible.

Outcomes

Primary Outcomes

Not specified

Similar Trials